{"id":"W4412620438","doi":"10.1182/bloodadvances.2024015014","title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Pharmacyclics; Eurostars; Genentech; Health Resources and Services Administration; Aptitude Health; Seagen; Incyte; Juno Therapeutics; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Gateway for Cancer Research; Celgene; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Alexion Pharmaceuticals; Spectrum Pharmaceuticals; Mallinckrodt Pharmaceuticals; Kite Pharma; Society for Immunotherapy of Cancer; Astellas Pharma US; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Bendamustine; Mantle cell lymphoma; Cumulative incidence; Oncology; Confidence interval; Salvage therapy; Odds ratio; Melphalan; Gastroenterology; Lymphoma; Surgery; Transplantation; Chemotherapy; Rituximab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003519161,0.0002364679,0.0009528131,0.0008363145,0.00009059103,0.00001716943,0.00025032,0.00009613335,0.000811859],"category_scores_gemma":[0.0001732828,0.0001773828,0.0004283064,0.001869578,0.0001260198,0.0001122047,0.00007330925,0.0001156823,0.000006649371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001010038,"about_ca_system_score_gemma":0.0003858145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002654837,"about_ca_topic_score_gemma":0.001050491,"domain_scores_codex":[0.9980674,0.00006430601,0.0005583874,0.0004817629,0.0004199012,0.000408183],"domain_scores_gemma":[0.9980413,0.0006861803,0.0002053758,0.0007396956,0.0002048518,0.0001225572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.007441376,0.007021856,0.4512897,0.003132276,0.009529235,0.0001767125,0.0004686051,0.0001039243,0.3776115,0.0008082351,0.002983446,0.1394331],"study_design_scores_gemma":[0.02575204,0.001542617,0.3024375,0.0002602939,0.007935948,0.000006718378,0.0005347445,0.0004509042,0.4028043,0.0004243827,0.257301,0.0005494983],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9294157,0.006203741,0.0006131905,0.0008560135,0.000389732,0.001654665,0.0001656519,0.0001911242,0.06051017],"genre_scores_gemma":[0.6190581,0.002536795,0.006736313,0.0002812,0.0001056927,0.0001829029,0.000096731,0.00004888052,0.3709534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3104432,"threshold_uncertainty_score":0.8889287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02176219910519934,"score_gpt":0.3536270628012587,"score_spread":0.3318648636960594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}